دورية أكاديمية
Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia.
| العنوان: | Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia. |
|---|---|
| المؤلفون: | Adawiyah RA; School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. Biah.Adawiyah@monash.edu.; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia. Biah.Adawiyah@monash.edu., Bradshaw CS; School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia., Vodstrcil LA; School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia., Fairley CK; School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia., Zhang L; School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. lei.zhang1@monash.edu.; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia. lei.zhang1@monash.edu.; Clinical Medical Research Center, Children's Hospital of Nanjing Medical University, Nanjing Medical University, 210008, Nanjing, Jiangsu, China. lei.zhang1@monash.edu., Ong JJ; School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. Jason.Ong@monash.edu.; Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia. Jason.Ong@monash.edu.; Faculty of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK. Jason.Ong@monash.edu. |
| المصدر: | Scientific reports [Sci Rep] 2024 Jun 04; Vol. 14 (1), pp. 12856. Date of Electronic Publication: 2024 Jun 04. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
| مواضيع طبية MeSH: | Mycoplasma genitalium*/drug effects , Mycoplasma Infections*/drug therapy , Mycoplasma Infections*/economics , Mycoplasma Infections*/microbiology , Cost-Benefit Analysis* , Anti-Bacterial Agents*/therapeutic use , Anti-Bacterial Agents*/economics , Anti-Bacterial Agents*/pharmacology , Drug Resistance, Bacterial*, Humans ; Australia/epidemiology ; Female ; Male ; Azithromycin/therapeutic use ; Azithromycin/economics ; Quality-Adjusted Life Years ; Adult ; Macrolides/therapeutic use ; Macrolides/economics |
| مستخلص: | The recommended first-line treatment for Mycoplasma genitalium infections is azithromycin. However, the prevalence of macrolide resistance for M. genitalium has increased to more than 50% worldwide. In 2013, Australia introduced a resistance-guided therapy (RGT) strategy to manage M. genitalium infections. This study assesses the cost-effectiveness of the RGT approach compared to no RGT (i.e., without macrolide resistance profile test) in women, men who have sex with men (MSM), and men who have sex with women (MSW) in Australia. We constructed dynamic transmission models of M. genitalium infections in women, MSM, and MSW in Australia, each with a population of 100,000. These models compared the costs and quality-adjusted life-years (QALYs) gained between RGT and no RGT scenarios from a healthcare perspective over ten years. All costs are reported in 2022 Australian dollars (Australian $). In our model, RGT is cost saving in women and MSM, with the incremental net monetary benefit of $1.3 million and $17.9 million, respectively. In MSW, the RGT approach is not cost-effective, with an incremental cost-effectiveness ratio of -$106.96 per QALY gained. RGT is cost saving compared to no RGT for M. genitalium infections in women and MSM, supporting its adoption as the national management strategy for these two population groups. (© 2024. The Author(s).) |
| References: | Clin Infect Dis. 2022 Sep 14;75(5):813-823. (PMID: 34984438) Emerg Infect Dis. 2015 Jun;21(6):960-8. (PMID: 25989525) Clin Infect Dis. 2023 Nov 17;77(10):1449-1459. (PMID: 37402645) Clin Infect Dis. 2013 Apr;56(8):1094-100. (PMID: 23300236) Sex Health. 2023 Feb;20(1):1-8. (PMID: 36356948) Clin Infect Dis. 2015 Aug 1;61(3):418-26. (PMID: 25900174) J Infect Dis. 2017 Jul 15;216(suppl_2):S396-S405. (PMID: 28838074) PLoS Pathog. 2011 May;7(5):e1001324. (PMID: 21637847) Emerg Infect Dis. 2019 Apr;25(4):719-727. (PMID: 30882306) J Pathog. 2014;2014:183167. (PMID: 25614838) BJOG. 2016 Jun;123(7):1194-202. (PMID: 26307516) Open Forum Infect Dis. 2020 Jul 13;7(8):ofaa291. (PMID: 32782911) Clin Microbiol Infect. 2016 Mar;22(3):260-5. (PMID: 26686807) Lancet Infect Dis. 2022 Sep;22(9):e267-e270. (PMID: 35325618) Int J Epidemiol. 2015 Dec;44(6):1982-94. (PMID: 26534946) Nat Rev Urol. 2017 Mar;14(3):139-152. (PMID: 28072403) Clin Infect Dis. 2011 Dec;53 Suppl 3:S129-42. (PMID: 22080266) Clin Infect Dis. 2020 Sep 12;71(6):1461-1468. (PMID: 31629365) Sex Transm Dis. 2020 Jun;47(6):409-411. (PMID: 32209955) J Eur Acad Dermatol Venereol. 2022 May;36(5):641-650. (PMID: 35182080) Sex Transm Infect. 2018 Jun;94(4):255-262. (PMID: 29440466) Clin Infect Dis. 2019 Feb 1;68(4):554-560. (PMID: 29873691) Sex Transm Infect. 2022 Mar;98(2):115-120. (PMID: 33782146) Sex Transm Infect. 2023 Aug 17;99(6):398-403. (PMID: 36958826) Lancet Infect Dis. 2020 Nov;20(11):1302-1314. (PMID: 32622378) Sex Transm Dis. 2018 Aug;45(8):522-526. (PMID: 29465653) Clin Infect Dis. 2010 Nov 15;51(10):1160-6. (PMID: 20942656) Sci Rep. 2021 May 27;11(1):11087. (PMID: 34045569) Sci Rep. 2020 Feb 25;10(1):3420. (PMID: 32098988) EClinicalMedicine. 2021 Mar 03;33:100779. (PMID: 33842867) Sex Transm Infect. 2022 Jun;98(4):277-285. (PMID: 34210839) |
| معلومات مُعتمدة: | GNT1193955 the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant; GNT1193955 the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 83905-01-5 (Azithromycin) 0 (Macrolides) |
| تواريخ الأحداث: | Date Created: 20240604 Date Completed: 20240604 Latest Revision: 20240607 |
| رمز التحديث: | 20240607 |
| مُعرف محوري في PubMed: | PMC11150248 |
| DOI: | 10.1038/s41598-024-63056-1 |
| PMID: | 38834637 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-024-63056-1 |